Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis
Journal Title: Annals of Hepatology - Year 2007, Vol 6, Issue 3
Abstract
Fibrosing cholestatic hepatitis (FCH) is an aggressive and usually fatal form of viral hepatitis in immunocompromised patients. It is characterized by progressive cholestasis leading to hepatic failure, and a characteristic histopathological features including: periportal fibrosis, ballooning degeneration of hepatocytes, cholestasis, with minimal inflammation. FCH has been reported almost exclusively in heavily immunosuppressed organ transplant recipients or patients with AIDS. This case report describes a previously immunocompetent patient with previously stable chronic hepatitis C who developed fibrosing cholestatic hepatitis after receiving cyclophosphamide and corticosteroids for active glomerulonephritis.
Authors and Affiliations
Faisal Saleh, Hin Ko, Jennifer Davis, Wichian Apiratpracha, James Powell, Siegfried Erb, Eric Yoshida
Keywords
Related Articles
- EP ID EP77786
- DOI -
- Views 125
- Downloads 0
Isolated granulomatous hepatitis-A histopathological surprise mimicking cholangiocarcinoma in ulcerative colitis
A 63-yr-old woman, known case of ulcerative colitis, was diagnosed with sclerosing cholangitis 2 years back. She was admitted for investigation of abdominal discomfort, fatigue with elevated alkaline phosphatase and dera...
Chemokines: potent mediators of hepatic inflammation and fibrosis in chronic liver diseases
Citrus auraptene: A potential multifunctional therapeutic agent for nonalcoholic fatty liver disease
Symptoms of Daytime Sleepiness and Sleep Apnea in Liver Cirrhosis Patients
Background/propose. Sleep disturbance and excessive daytime sleepiness (EDS) have been reported in patients with hepatic cirrhosis with no hepatic encephalopathy (HE). The objective of this study was to evaluate daytime...
Primary care practitioners survey of non-alcoholic fatty liver disease
Background. The rising incidence of non alcoholic fatty liver disease (NAFLD) mirrors the epidemics of obesity and metabolic syndrome. Primary care practitioners (PCPs) are central to management of patients with NAFLD, b...